Resverlogix Corp. (TSE:RVX – Get Free Report)’s share price hit a new 52-week low on Thursday . The stock traded as low as C$0.04 and last traded at C$0.05, with a volume of 3000 shares trading hands. The stock had previously closed at C$0.04.
Resverlogix Stock Performance
The company has a debt-to-equity ratio of -10.95, a current ratio of 0.13 and a quick ratio of 0.04. The stock has a market capitalization of C$8.91 million, a P/E ratio of -2.23 and a beta of 0.71. The company has a fifty day moving average of C$0.05 and a two-hundred day moving average of C$0.06.
Resverlogix Company Profile
Resverlogix Corp clinical-stage biotechnology company. The company is developing an advanced epigenetic drug called apabetalone for the treatment of patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, peripheral artery disease, orphan diseases, and neurodegenerative diseases.
See Also
- Five stocks we like better than Resverlogix
- What is a Secondary Public Offering? What Investors Need to Know
- Autodesk Designs Value for Investors: Uptrend Set to Continue
- How to Use the MarketBeat Excel Dividend Calculator
- Anheuser-Busch Stock Rallies—Is the King of Beers Back?
- How to Effectively Use the MarketBeat Ratings Screener
- MarketBeat Week in Review – 02/24 – 02/28
Receive News & Ratings for Resverlogix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Resverlogix and related companies with MarketBeat.com's FREE daily email newsletter.
